330 related articles for article (PubMed ID: 37291377)
1. Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.
Galve-Calvo E; Alonso-Babarro A; Martínez-García M; Pi-Figueras M; Villalba G; Alonso S; Contreras J
Adv Ther; 2023 Aug; 40(8):3304-3331. PubMed ID: 37291377
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
5. How we treat HER2-positive brain metastases.
Stavrou E; Winer EP; Lin NU
ESMO Open; 2021 Oct; 6(5):100256. PubMed ID: 34482180
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
7. New target therapies for brain metastases from breast cancer.
Metro G; Fabi A
Curr Cancer Drug Targets; 2012 Mar; 12(3):210-7. PubMed ID: 22268385
[TBL] [Abstract][Full Text] [Related]
8. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?
Fontanella C; De Carlo E; Cinausero M; Pelizzari G; Venuti I; Puglisi F
Cancer Treat Rev; 2016 May; 46():80-8. PubMed ID: 27218867
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
11. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Gonzalez-Angulo AM; Kirshner JJ; Krop I; Levinson J; Modi S; Patt DA; Perez EA; Perlmutter J; Winer EP; Lin NU
J Clin Oncol; 2014 Jul; 32(19):2100-8. PubMed ID: 24799487
[TBL] [Abstract][Full Text] [Related]
12. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH
J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
14. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients.
Fokas E; Henzel M; Hamm K; Grund S; Engenhart-Cabillic R
Tumori; 2012 Nov; 98(6):768-74. PubMed ID: 23389365
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
Hackshaw MD; Danysh HE; Henderson M; Wang E; Tu N; Islam Z; Ladner A; Ritchey ME; Salas M
BMC Cancer; 2021 Aug; 21(1):967. PubMed ID: 34454469
[TBL] [Abstract][Full Text] [Related]
17. Current Treatment Options for Breast Cancer Brain Metastases.
Raghunath A; Desai K; Ahluwalia MS
Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009
[TBL] [Abstract][Full Text] [Related]
18. Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM; Cullen GD; O'Sullivan CC
CA Cancer J Clin; 2020 Sep; 70(5):355-374. PubMed ID: 32813307
[TBL] [Abstract][Full Text] [Related]
19. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
